Galecto Inc
NASDAQ:GLTO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Galecto Inc
Other Current Liabilities
Galecto Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galecto Inc
NASDAQ:GLTO
|
Other Current Liabilities
$604k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Other Current Liabilities
kr1.1B
|
CAGR 3-Years
65%
|
CAGR 5-Years
42%
|
CAGR 10-Years
34%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Current Liabilities
kr295.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
20%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Current Liabilities
€492.2m
|
CAGR 3-Years
122%
|
CAGR 5-Years
83%
|
CAGR 10-Years
66%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Current Liabilities
kr21m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-26%
|
|
|
Saniona AB
STO:SANION
|
Other Current Liabilities
kr23.9m
|
CAGR 3-Years
100%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Galecto Inc
Glance View
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. The firm is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.
See Also
What is Galecto Inc's Other Current Liabilities?
Other Current Liabilities
604k
USD
Based on the financial report for Dec 31, 2024, Galecto Inc's Other Current Liabilities amounts to 604k USD.
What is Galecto Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-33%
Over the last year, the Other Current Liabilities growth was -51%. The average annual Other Current Liabilities growth rates for Galecto Inc have been -33% over the past three years , -33% over the past five years .
